Royal London Asset Management
RGLS

Royal London Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Royal London Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-347
Closed -$382K – 536
2015
Q4 		$382K Buy
347
+100
+40% +$100K 0.01% 553
2015
Q3 		$194K Buy
+247
New +$254K ﹤0.01% 564
2014
Q4 		$4.82K Buy
+250
New +$445K 0.01% 515

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Royal London Asset Management's RGLS Position: Q1 2016 in Review

Royal London Asset Management sold out of Regulus Therapeutics (RGLS) in Q1 2016, closing a stake of 347 shares — an estimated $382K sold.

Royal London Asset Management first reported a position in RGLS in Q4 2014 and held it in 3 quarters. The position peaked at $382K in Q4 2015. 101 funds tracked by Wall St. Rank hold RGLS as of Q1 2016.

  • Royal London Asset Management reported no remaining Regulus Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Royal London Asset Management sold 347 Regulus Therapeutics shares in Q1 2016, an estimated $382K.
  • Royal London Asset Management first reported a position in Regulus Therapeutics in Q4 2014 and held it in 3 quarters.
  • Royal London Asset Management's Regulus Therapeutics position peaked at $382K in Q4 2015.
  • 101 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2016.

Based on Royal London Asset Management's 13F filing for Q1 2016, filed 17 May 2016.